BOSTON & MONTREAL, December 30, 2024--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company ...

Shares of ENGN stock opened at $5.96 on Monday. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The stock’s 50-day moving average is $8.13 and its two-hundred day ...

ENGN opened at $6.32 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. enGene has a fifty-two week low of $4.42 and a fifty-two week ...

enGene Holdings Inc. (ENGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of enGene (ENGN) with a Buy rating and $25 price target The firm says the The non-muscle invasive bladder cancer treatment landscape is ...

enGene (ENGN) is in a strong clinical and financial position as we close the year,” said Ron Cooper, Chief Executive Officer of enGene. “With trial recruitment open across all cohorts ...

BOSTON & MONTREAL, December 30, 2024--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational ...

On Monday, H.C. Wainwright began coverage on Engene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a price target of $25.00. The firm's analyst highlighted the potential of enGene's gene ...

enGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet ...

BOSTON & MONTREAL, December 19, 2024--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead ...